Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02530749

Enrollment

265

Registered

2015-08-21

Start date

2014-04-30

Completion date

2019-03-31

Last updated

2019-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumors

Keywords

Surgery, Frailty

Brief summary

Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current perioperative risk models.

Detailed description

Preoperative risk assessment is important, but inexact, in older patients because physiologic reserves are difficult to measure. This also makes an important difference related to brain tumor patients, who may be burdened with systemic disease, alterations in cognition, or affected by other comorbidities. When assessing quality of life for brain tumor patients, having a better predictor of postsurgical outcome would be beneficial in appropriately counseling these patients. Frailty is thought to estimate physiologic reserves, and its use has been found to predict postoperative complications, length of stay, and discharge to a skilled or assisted-living facility in neurosurgical patients. Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current perioperative risk models.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult * Ambulatory (able to walk) * Scheduled for neurosurgical resection of brain tumor

Exclusion criteria

* Parkinson disease * Previous stroke * Taking: carbidopa/levodopa, donepezil hydrochloride, or antidepressants

Design outcomes

Primary

Measure	Time frame	Description
Number of patients with a Complication risk	30 days	Number of patients with a complication risk based on a Hopkins Frailty Score (HFS).

Secondary

Measure	Time frame	Description
Length of stay based on a Hopkins Frailty Score (HFS).	30 days	Number of patients with a prolonged length of stay based on a Hopkins Frailty Score (HFS).
Number of patients Discharge to a skilled or assisted-living facility	30 days	Number of patients discharged to a skilled or assisted-living facility based on a Hopkins Frailty Score (HFS).

Countries

United States

Outcome results